Key Market Segments:
By Source
-
Microbial
-
Mammalian
-
Others
By Product
-
Monoclonal Antibodies
-
MABs by Application
-
Diagnostic
-
Biochemical Analysis
-
Diagnostic Imaging
-
-
Therapeutic
-
Direct MAB Agents
-
Targeting MAB Agents
-
-
Protein Purification
-
Others
-
-
MABs by Type
-
Murine
-
Chimeric
-
Humanized
-
Human
-
Others
-
-
-
Vaccines
-
Recombinant Proteins
-
Antisense & RNAi Therapeutics
-
Others
By Disease Category
-
Oncology
-
Infectious Diseases
-
Immunological Disorders
-
Cardiovascular Disorders
-
Hematological Disorders
-
Others
By Manufacturing
-
Outsourced
-
In-house
Regional Coverage:
North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Poland
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- ASEAN Countries
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Mexico
- Colombia
- Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g. Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
Ans: North America dominated the Biologics Market in 2025 with approximately 45% revenue share, while Asia-Pacific is expected to register the fastest CAGR through 2035.
Ans: Monoclonal Antibodies dominated with approximately 45% revenue share in 2025, while Antisense & RNAi Therapeutics is the fastest-growing product segment through 2035.
Ans: Growth is driven by rising prevalence of chronic and complex diseases, continuous biotechnology innovation, expanding biosimilar adoption, increasing focus on personalized medicine, and regulatory support for expedited biologic approvals globally.
Ans: The Market was valued at USD 519.72 Billion in 2025 and is projected to reach USD 1,283.29 Billion by 2035.
Ans: The Biologics Market is expected to grow at a CAGR of 9.46% during 2026–2035.